Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 1 Trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 6, p. s445, 2024. DOI: 10.25251/skin.8.supp.445. Disponível em: https://skin.dermsquared.com/skin/article/view/3082. Acesso em: 7 nov. 2025.